Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS

Mutations activating KRAS underlie many forms of cancer, but are refractory to therapeutic targeting. Here, we develop Poloppin, an inhibitor of protein-protein interactions via the Polo-box domain (PBD) of the mitotic Polo-like kinases (PLKs), in monotherapeutic and combination strategies to target...

Descripción completa

Detalles Bibliográficos
Autores principales: Narvaez, Ana J., Ber, Suzan, Crooks, Alex, Emery, Amy, Hardwick, Bryn, Guarino Almeida, Estrella, Huggins, David J., Perera, David, Roberts-Thomson, Meredith, Azzarelli, Roberta, Hood, Fiona E., Prior, Ian A., Walker, David W., Boyce, Richard, Boyle, Robert G., Barker, Samuel P., Torrance, Christopher J., McKenzie, Grahame J., Venkitaraman, Ashok R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563081/
https://www.ncbi.nlm.nih.gov/pubmed/28807782
http://dx.doi.org/10.1016/j.chembiol.2017.07.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563081/
https://www.ncbi.nlm.nih.gov/pubmed/28807782
http://dx.doi.org/10.1016/j.chembiol.2017.07.009

Ejemplares similares